Rachel Carmen Ceasar1, Alex H Kral2, Kelsey Simpson3, Lynn Wenger2, Jesse L Goldshear3, Ricky N Bluthenthal3. 1. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA, 90032, USA. Electronic address: rceasar@usc.edu. 2. Behavioral Health Research Division, RTI International, 2150 Shattuck Avenue, Suite 800, Berkeley, CA, 94704, USA. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA, 90032, USA.
Abstract
OBJECTIVE: Cannabis motivations have been studied extensively among patients of medicinal cannabis dispensaries, but less is known about motivations in community samples of opioid-using people who inject drugs. Our objective is to describe cannabis use motivations associated with self-treatment of physical pain, emotional issues, and as an opioid substitute. METHODS: Data come from 6-month follow-up interviews with people who inject drugs who participated in a study on the efficacy of an injection initiation prevention intervention in Los Angeles and San Francisco, California from 2016-18. The analytic sample consists of 387 people who inject drugs who reported past-month cannabis use. We developed multivariable logistic regression models by reported cannabis use motivations: physical pain relief, emotional problems, and opioid substitute. RESULTS: The most common cannabis use motivations reported by people who inject drugs was to "get high," relieve physical pain and emotional problems, and reduce opioid use. In separate multivariate models, using cannabis for physical pain relief was associated with higher odds of using cannabis as a substitute for opioids; cannabis for emotional problems was associated with being diagnosed with depression; and cannabis as a substitute for opioids was associated with non-prescribed, non-injection methadone use. CONCLUSION: People who inject drugs reported using cannabis for health-related motivations. This motivation aligns with health needs and suggests the acceptability of cannabis use for health reasons in this population. Studies to determine the medical effectiveness of cannabis products for these common health and mental health needs among people who inject drugs are needed.
OBJECTIVE: Cannabis motivations have been studied extensively among patients of medicinal cannabis dispensaries, but less is known about motivations in community samples of opioid-using people who inject drugs. Our objective is to describe cannabis use motivations associated with self-treatment of physical pain, emotional issues, and as an opioid substitute. METHODS: Data come from 6-month follow-up interviews with people who inject drugs who participated in a study on the efficacy of an injection initiation prevention intervention in Los Angeles and San Francisco, California from 2016-18. The analytic sample consists of 387 people who inject drugs who reported past-month cannabis use. We developed multivariable logistic regression models by reported cannabis use motivations: physical pain relief, emotional problems, and opioid substitute. RESULTS: The most common cannabis use motivations reported by people who inject drugs was to "get high," relieve physical pain and emotional problems, and reduce opioid use. In separate multivariate models, using cannabis for physical pain relief was associated with higher odds of using cannabis as a substitute for opioids; cannabis for emotional problems was associated with being diagnosed with depression; and cannabis as a substitute for opioids was associated with non-prescribed, non-injection methadone use. CONCLUSION: People who inject drugs reported using cannabis for health-related motivations. This motivation aligns with health needs and suggests the acceptability of cannabis use for health reasons in this population. Studies to determine the medical effectiveness of cannabis products for these common health and mental health needs among people who inject drugs are needed.
Authors: William T Robinson; Jan M H Risser; Shanell McGoy; Adam B Becker; Hafeez Rehman; Mary Jefferson; Vivian Griffin; Marcia Wolverton; Stephanie Tortu Journal: J Urban Health Date: 2006-11 Impact factor: 3.671
Authors: Hudson Reddon; Kora DeBeck; Maria Eugenia Socias; Huiru Dong; Evan Wood; Julio Montaner; Thomas Kerr; Michael-John Milloy Journal: Drug Alcohol Rev Date: 2018-02-12
Authors: Andrew H Rogers; Jafar Bakhshaie; Julia D Buckner; Michael F Orr; Daniel J Paulus; Joseph W Ditre; Michael J Zvolensky Journal: J Addict Med Date: 2019 Jul/Aug Impact factor: 3.702
Authors: Chris Beyrer; Zeenat Patel; Julie A Stachowiak; Farida K Tishkova; Mark A Stibich; Lindsay M Eyzaguirre; Jean K Carr; Vladimir Mogilnii; Alena Peryshkina; Alisher Latypov; Steffanie A Strathdee Journal: AIDS Res Hum Retroviruses Date: 2009-09 Impact factor: 2.205
Authors: Stephanie Lake; Zach Walsh; Thomas Kerr; Ziva D Cooper; Jane Buxton; Evan Wood; Mark A Ware; M J Milloy Journal: PLoS Med Date: 2019-11-19 Impact factor: 11.069